Ljubljana 2014 Registration Programme Satellite Meetings Exhibition Hotel Information Virtual Exhibition Visa Information
Back to Freepaper Session

Refractive lens exchange with trifocal IOL implantation

Session Details

Session Title: Refractive

Session Date/Time: Sunday 16/02/2014 | 08:30-11:00

Paper Time: 10:36

Venue: Kosovel Hall (Level -2)

First Author: : IvaDekaris CROATIA

Co Author(s): :    Ante Barisic   Nikica Gabric           

Abstract Details


We present results after refractive lens exchange with implantation of AT LISA tri 839MP intraocular lens to presbyopic patients


Specialty Eye Hospital ""Svjetlost"", Zagreb, Croatia; Medical School, University of Rijeka, Rijeka, Croatia


Fifty two patients underwent bilateral AT LISA tri 839MP implantation (104 eyes) after clear lens extraction. Patients were presbyopes, 47 hypermetropes and 5 myopes, between 46 and 68 years. Uncorrected distance visual acuity (UCDVA), uncorrected intermediate visual acuity at 80 cm (UCIVA), uncorrected near visual acuity (UCNVA), uncorrected distance visual acuity under 10% contrast level, visual disturbances and subjective satisfaction were measured and compared to Bifocal group (AT LISA 809MP ; 42 pts, 84 eyes) . Follow up was at least six months


All patients with trifocal IOL achieved monocular UCDVA better than 0.1 logMAR, (76,9% eyes 0.0 logMAR). Monocular UCIVA better than 0.2 logMAR achieved 96,1% patients (37,5% patients 0.0 logMAR). J2 and better could read all patients (72,1% patients J1). UCDVA at 10% contrast level was also excellent, 62.5% of patients can read 0.0 logMAR. Halo and glare were reported in less than 10% of patients, there was no need for LASIK/PRK enhancement. Spherical equivalent was equal or less than 0.5D and 96% of patients would implant the same lens again.


Refractive lens exchange with implantation of ATLISA tri 839MP enables good vision at all distances and enables spectacle independence. It is excellent choice for younger, active presbyopes who have need for good intermediate vision. FINANCIAL INTEREST: NONE